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This report resumes three cases of Churg-Strauss Syndrome (CSS) illustrating the challenges 
associated with cardiac manifestation of this disease. Here, we exemplify the role of cardiac 
magnetic resonance (CMR) for diagnosis and follow-up of CSS with a focus on new non-
contrast T2-weighted imaging sequences for quantification of myocardial scar tissue and 
quantitative T2 mapping techniques, which allow the detection of myocardial edema.  
  
 
Churg-Strauss Syndrome (CSS) or “eosinophilic granulomatosis with polyangiitis” (EGPA) is 
a very rare systemic disease affecting people between 40-60 years old. Typical lesions of CSS 
are histologically characterized by eosinophilia, necrotizing or granulomatous vascular 
lesions, and extravascular granulomas. Since distinct diagnostic criteria are missing, CSS 
syndrome is diagnosed on the basis of the presence of different clinical signs, which in their 
entity separate CSS from other forms of vasculitis (Lahnam’s criteria, 1990 ACR classification, 
Chapel Hill’s classification)1,2. CSS is known for 3 clinical phases: the “prodromic” phase with 
eosinophilic upper airway involvement, the “eosinophilic” phase with peripheral eosinophilia 
and peripheral organ involvement, and the “vasculitic” phase. These 3 phases may overlap or 
appear in a variable sequence. Serological markers of CSS are ANCA (essentially pANCA), 
which are prevalent in 40% of EGPA cases but less in patients with cardiac involvement. 
Serum IgE levels are usually elevated, and IgG4 occur in 75% of all cases3,4. Usually, C-
reactive protein (CRP) and erythrocyte sedimentation rate are increased only in the acute 
phase. Furthermore, eosinophilic cationic protein (ECP) may be elevated in EGPA, and, if so, 
ECP is useful for monitoring of disease activity5,6.  
 
Cardiac manifestation of CSS has been reported with a prevalence of 66%7, however, post-
mortem studies suggest a prevalence up to 92%4. In 50% of all CSS cases, mortality is 
associated with cardiac manifestation of the disease presenting as progressive 
perimyocarditis, myocardial infarction or heart failure. Corticosteroids and long-term 
immunosuppression may improve event-free and disease-free survival rates in patients with 
cardiac manifestations of CSS4.  
 
In the last years, CMR has emerged as a highly valuable tool for diagnosis of cardiac 
involvement in CSS and for monitoring of treatment7-11. CMR enables not only functional 
characterization but also pathomorphological assessment such as detection of myocardial 
edema in CSS myocarditis, or quantification of myocardial fibrosis or scar tissue secondary to 
coronaritis or coronary occlusion. The following three cases will illustrate application of CMR 
for detection of cardiac manifestation of CSS at our institution.  
 
The first case is a 40-year-old male known for longstanding severe non-reversible obstructive 
lung disease with epistaxis and hemoptysis and a history of hypereosinophilia. The initial 
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echocardiogram showed a severely reduced left ventricular ejection fraction (LVEF) with 
lateral/posterior akinesia and severe functional mitral regurgitation. The CMR study 
demonstrated widespread, predominantly subendocardial, late gadolinium enhancement 
(LGE), the coronary angiogram was without significant pathology. The chest-CT revealed 
fibro-emphysema and some ground glass infiltrates. The bronchoalveolar lavage 
demonstrated eosinophilia, neutrophilia and hemosiderosis consistent with chronic 
inflammation and low grade bronchoalveolar hemorrhage. An extensive laboratory work-up 
revealed elevation of IgE (175 U/L; N<100U/L) and ECP (ECP: 19.8 μg/l; N<16 μg/l). A right 
ventricular endomyocardial biopsy (EMB) demonstrated lymphocytic and eosinophilic 
infiltrates and signs of subacute myocarditis while granuloma or vasculitis were absent. CSS 
with cardiac involvement was suspected and treated with prednisone 1 mg/kg (with 
progressive tapering) and mycophenolate mofetil (MMF) in addition to optimal medical 
treatment for LV systolic dysfunction. Subsequently, ECP normalized rapidly. Serial CMR 
studies demonstrated stable LGE lesions in concordance with the histologic regression of the 
lymphocytic and eosinophilic infiltrates on the EBM procured after 6 months of 
immunosuppression. Because of a persistent severe LV dysfunction with left bundle branch 
block and non-sustained VT episodes, a CRT-D was implanted. Long term stabilization in 
NHYA functional class II-III was obtained, with mixed cardiac and respiratory limitations. 
 
The second case is a 41-year-old woman treated for hypothyroidism, known for fatigue and 
palpitations of a few weeks duration in 2009, and high incidence of polymorphic ventricular 
extrasystoles. The echocardiogram showed a LVEF of 50% with thinning of the basal 
interventricular septum. CMR demonstrated thinning and akinesia of the basal segments of 
the anterior/antero-septal walls, with transmural LGE. The patient presented a borderline 
hypereosinophilia (6% N ≤ 5) and increase of ECP (20.3 μg/l; N<16 μg/l); ANCA were 
negative. Pulmonary function tests showed mild obstructive syndrome without reversibility. 
The bronchoalveolar lavage showed a discrete eosinophilia. A right ventricular EBM was 
without inflammatory lesions. CSS was suspected and the patient was treated with prednisone 
(starting 1mg/kg) and MMF with rapid normalization of ECP and stability of the cardiac function 
and LGE distribution on repeated CMR studies. An ICD was implanted after arrival of an 
exertion-induced syncope and a positive electrophysiology study.  
 
The third case is a 53-year-old obese female with a history of gastric bypass in 2004, 
presenting with acute chest pain and dyspnea in January 2016. The ECG showed lateral ST 
segment depression with elevated high sensitive troponins T (peak: 814 ng/L; N< 14), creatine 
kinase (peak: 224 U/L), NT-proBNP (20’593 pg/ml) and CRP (62 mg/l); the coronary 
angiogram was normal. CMR imaging showed a non-dilated hypertrophic left ventricle with 
LVEF of 37%, mimicking hypertrophic cardiomyopathy (HCM). However, T1 mapping did not 
reveal fibrosis while T2-mapping showed diffuse edema of the LV myocardium suggesting 
acute myocarditis (fig. 1). Furthermore, a small pericardial effusion was noted. The patient 
was treated with ACE-inhibitors, beta-blockers, and initially high dose acetylic salicyl acid. 
Subsequently, LVEF normalized and myocardial edema as well as hypertrophy decreased in 
the control CMR at 10 days (fig. 1). The clinical evolution was remarkable for the appearance 
of a papulo-vesicular rash conjoint with peripheral hypereosinophilia (2.6 G/L), which was also 
present in the bone marrow examination (18%). Neoplasia or parasitic infection were 
excluded; the immunologic workup showed positive pANCA (1/80) and elevation of anti-MPO 
titers (26 CU) and ECP (44 μg/l). The skin biopsies showed neutrophilic infiltrates with 
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leukocytoclasia and an eosinophilic perivascular infiltrate. A right ventricular EMB showed a 
predominantly lymphocytic infiltrate with rare eosinophils without granuloma or signs of 
vasculitis. Chest CT and pulmonary function testing were unremarkable. CSS was suspected 
and the patient was started on prednisone 1 mg/kg with good clinical response. Serial CMR 
studies showed progressive reduction of the LV hypertrophy and normalization of T2 
measurements (fig. 1). After progressive tapering of the prednisone to 30 mg/d, the patient 
was rehospitalized for dyspnea. A chest CT revealed ground glass in the left upper lobe with 
eosinophilia in the bronchoalveolar lavage. The prednisone was increased to 50 mg/d and 
methotrexate 12.5 mg/week was added, with progressive resolution of the lung infiltrate. 
 
The diagnosis of CSS remains challenging because most patients with cardiac involvement 
are ANCA-negative and initial clinical presentation may vary considerably. In any case, 
association of peripheral blood eosinophilia, evidence of past or present myocarditis and 
obstructive lung disease or lung infiltrates should raise the suspicion of CCS. But, peripheral 
eosinophilia may be absent or mild at the time of the diagnosis3,4.  
 
Altogether, the first two cases represent later stage CSS disease as indicated by the presence 
of myocardial scars tissue while the third case illustrates acute CSS. Vasculitis and granuloma 
were not present in myocardial or skin tissue in neither case, instead we observed lymphocytic 
and eosinophilic infiltration. This observation is compatible with the absence of renal and/or 
neurologic disease, which is usually related with typical small-vessel vasculitis. Therefore, we 
found that the term “Churg-Strauss syndrome” seems to resume these cases more adequately 
while EGPA is associated with vasculitis and granuloma. In fact, this discordance might reflect 
that CSS and EGPA are distinct nosologic entities with different clinical presentations. 
 
In summary, the approach for the diagnosis and follow-up of CSS at our institution is based 
on laboratory markers (eosinophil count, ESR, CRP, ANCA, ECP), echocardiography and 
CMR, which has been proven as valuable tool in CCS patients7,8,11,12. However, EMB 
procurement is used exclusively for the initial work-up since the new techniques for tissue-
characterization have become available at our institution (fig. 2). More recently, these 
techniques have also been applied for detection of cardiac manifestation of connective tissue 
diseases13. Inflammatory heart disease typically demonstrates subepicardial LGE-positive 
lesions14.  
 
The evaluation of CMR in CSS has to consider that LGE is observed at mid-wall, transmural, 
epicardial, and often subendocardial localisation15,16, which may reflect coronaritis or coronay 
spasm related with CSS17. Since subendocardial LGE is a hallmark of ischemic heart disease, 
coronary disease should always be ruled out, particularly when LGE distribution matches to a 
specific coronary territory. T2-weighted images for edema detection allow for discrimination of 
acute from chronic lesions, thus, should always be included in the follow-up of cardiac 
CSS15,17,18,19. Quantitative T2 mapping can even improve sensitivity for edema detection20. At 
our center, we always include T1 mapping in CMR based assessment of CSS because 
extracellular volume fraction (ECV) correlates well with histological indices of interstitial 
myocardial fibrosis, which is often increased in EGPA patients with decreased LVEF11. In case 
of contra-indications to MRI, FDG-PET may constitute an interesting alternative10.  
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CMR has become a useful diagnostic tool for detection and follow-up of cardiac manifestation 
of CCS. It remains to be shown whether CMR-guided follow-up of cardiac CSS translates in 
improvement of treatment and prognosis. 
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Fig. 1 CMR imaging of case 3 at diagnosis (first raw), after 10 days (second raw) and 2 months (third 
raw) follow-up. 
 First column: Pictures extracted from the cine views demonstrating the left ventricular hypertrophy 
and initially edematous appearance of the myocardium (upper picture). The progressive reduction 
of the measured LV mass is also shown below. 
 Second column: The upper picture is extracted from T2-weighted images. This first study was 
performed on a machine not allowing T2 mapping. Nevertheless, a higher T2 signal can be 
demonstrated in the myocardium. In the next two MRI studies, quantitative T2 mapping was 
performed, demonstrating progressive normalization of the T2 values (N≤ 50ms) in favor of the 
resolution of the edema. 
 Third column: T1 mapping with quantification of the extracellular volume (ECV). 
 Fourth columns: LGE sequence demonstrating an abnormal grey and edematous appearance of 
the myocardium, without diffuse contrast enhancement. 
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Fig. 2 Suggested initial diagnostic work-up in case of a suspected Churg-Strauss syndrome with cardiac 
involvement: 
 The suggested initial multi-systemic evaluation is illustrated (four boxes of the left raw). A CMR 
is included in the cardiological assessment. CMR findings (LVEF, LGE, T2 mapping) are then 
integrated to stratify the probability of a cardiac involvement and guide further investigations 
and therapy.  
 If myocardial edema (T2 mapping) or LGE lesions are detected, endomyocardial biopsies of 
these lesions should be considered (if feasible with an acceptable peri-procedural risk). If their 
distribution is transmural of subendocardial, a coronary angiogram should also be  performed 
to rule out coronary artery disease.  
(CMR: Cardiac Magnetic Resonance, SR: Sedimentation rate, ECP: Eosinophil Cationic Protein, LGE: Late 
Gadolinium Enhancement) 
 
 
SUSPECTED CHURG-STRAUSS WITH CARDIAC INVOLVEMENT 
• Cardiomyopathy (myocarditis) 
• Obstructive lung disease (or lung infiltrates) 
• Eosinophilia 
Immunological work-up: 
- SR, CRP 
- ANCA screening  
- Total IgE, IgG4 
- (ECP) 
Pneumological work-up: 
- Pulmonary function test 
- Chest RX +/- Chest CT 
- (Bronchoalveolar lavage) 
Cardiac work-up: 
- ECG 
- Echocardiography 
- BNP, troponin 
- Holter monitoring 
- CMR 
Nephrological work-up: 
- Creatinin, eGFR 
- Urinalysis  
- Screening for proteinuria 
Coronarography 
LGE 
epicardial, 
mid-wall 
transmural, 
subendocardial 
EMB T2 mapping increased value 
LOW 
absent 
normal 
LVEF reduced normal 
HIGH 
CMR FINDINGS: 
PROBABILITY 
